{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:34Z","timestamp":1777984294248,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09566-x","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:25:29Z","timestamp":1771820729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design of a card-based operational framework for the implementation of inclusive representation in clinical trials"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6910-4325","authenticated-orcid":false,"given":"Marisa","family":"Minetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylenia","family":"Paleari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Puebla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Cavatorta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fontani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Muzzopappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"9566_CR1","unstructured":"National Institute on Aging. What are clinical trials and studies? https:\/\/www.nia.nih.gov\/health\/clinical-trials-and-studies\/what-are-clinical-trials-and-studies. Accessed 20 May 2025."},{"issue":"1","key":"9566_CR2","first-page":"31","volume":"1","author":"JM Novitzke","year":"2008","unstructured":"Novitzke JM. The significance of clinical trials. J Vasc Interv Neurol. 2008;1(1):31\u20134.","journal-title":"J Vasc Interv Neurol"},{"issue":"12","key":"9566_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624\u201332.","journal-title":"JAMA"},{"key":"9566_CR4","doi-asserted-by":"crossref","unstructured":"Bibbins-Domingo K. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. Washington (DC): National Academies of Sciences, Engineering, and Medicine; 2022.","DOI":"10.17226\/26479"},{"issue":"3","key":"9566_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cpt.2804","volume":"113","author":"F Washington","year":"2023","unstructured":"Washington F, Huang ES, Mega JL, Abernethy AP. Diversity, equity, and inclusion in clinical research: a path toward precision health for everyone. Clin Pharmacol Ther. 2023;113(3):509\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9566_CR6","first-page":"311","volume":"34","author":"AE Mullin","year":"2021","unstructured":"Mullin AE, Coe IR, Gooden EA, Tunde-Byass M, Wiley RE. Inclusion, diversity, equity, and accessibility: from organizational responsibility to leadership competency. Leadersh Health Serv. 2021;34(6):311\u20135.","journal-title":"Leadersh Health Serv"},{"key":"9566_CR7","unstructured":"Harper J. Diversity in clinical trials: strategies and challenges. Applied Clinical Trials. https:\/\/www.appliedclinicaltrialsonline.com\/view\/diversity-in-clinical-trials-strategies-and-challenges. Accessed 25 May 2025."},{"issue":"5","key":"9566_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","volume":"44","author":"LT Clark","year":"2019","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL, Elmer M, Akinboboye O, Gorham M, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148\u201372.","journal-title":"Curr Probl Cardiol"},{"key":"9566_CR9","doi-asserted-by":"publisher","first-page":"1298437","DOI":"10.3389\/fphar.2023.1295281","volume":"14","author":"R Yakubov","year":"2023","unstructured":"Yakubov R, Pimenova D, Ahmed A, Corvacho R, Madigan J, Naik J, et al. Development of a clinical research educational training for community health workers using the joint task force for clinical trial competency framework. Front Pharmacol. 2023;14:1298437.","journal-title":"Front Pharmacol"},{"issue":"3","key":"9566_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/clpt.2008.144","volume":"84","author":"SM Huang","year":"2008","unstructured":"Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84(3):287\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"9566_CR11","unstructured":"Kuznar W. AACR\u2019s cancer disparities inaugural report addresses care inequities. Am Health Drug Benefits. https:\/\/www.ahdbonline.com\/web-exclusives\/aacr-s-cancer-disparities-inaugural-report-addresses-care-inequities. Accessed 12 Jun 2025."},{"issue":"1","key":"9566_CR12","doi-asserted-by":"publisher","first-page":"e000682","DOI":"10.1136\/bmjmed-2024-000984","volume":"3","author":"D Collister","year":"2024","unstructured":"Collister D, Song C, Ruzycki SM. Fostering diversity in clinical trials: need for evidence and implementation to improve representation. BMJ Med. 2024;3(1):e000682.","journal-title":"BMJ Med"},{"issue":"612","key":"9566_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3399\/bjgp13X668456","volume":"63","author":"S Redwood","year":"2013","unstructured":"Redwood S, Gill PS. Under-representation of minority ethnic groups in research: call for action. Br J Gen Pract. 2013;63(612):342\u20133.","journal-title":"Br J Gen Pract"},{"key":"9566_CR14","doi-asserted-by":"publisher","first-page":"107040","DOI":"10.1016\/j.cct.2023.107092","volume":"126","author":"S Versavel","year":"2023","unstructured":"Versavel S, Subasinghe R, Johnson J, Golonski D, Muhlhausen S, Perry P, et al. Diversity, equity, and inclusion in clinical trials: a practical guide from the perspective of a trial sponsor. Contemp Clin Trials. 2023;126:107040.","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"9566_CR15","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/all.16113","volume":"79","author":"H Suffian","year":"2024","unstructured":"Suffian H, Pandya A, Davidson L. Racial and ethnic representation in food allergen immunotherapy trial participants: a systematic review. Allergy. 2024;79(9):2567\u201378.","journal-title":"Allergy"},{"key":"9566_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s13063-021-05849-7","volume":"22","author":"DH Bodicoat","year":"2021","unstructured":"Bodicoat DH, Routen AC, Willis A, Ekezie W, Gillies C, Lawson C, et al. Promoting inclusion in clinical trials\u2014a rapid review of the literature and recommendations for action. Trials. 2021;22:880.","journal-title":"Trials"},{"issue":"1","key":"9566_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1740774518755054","volume":"15","author":"A Corneli","year":"2018","unstructured":"Corneli A, Hallinan Z, Hamre G, Perry B, Goldsack JC, Calvert SB, et al. The Clinical Trials Transformation Initiative: methodology supporting the mission. Clin Trials. 2018;15(1):13\u20138.","journal-title":"Clin Trials"},{"key":"9566_CR18","unstructured":"European Medicines Agency. Accelerating clinical trials in the EU: publication of the 2022\u20132026 workplan. https:\/\/www.ema.europa.eu\/en\/news\/accelerating-clinical-trials-eu-publication-2022-2026-workplan. Accessed 4 Jun 2025."},{"key":"9566_CR19","unstructured":"NHS Health Research Authority. Guidance on developing and submitting an inclusion and diversity plan (second draft). https:\/\/www.hra.nhs.uk\/about-us\/news-updates\/guidance-developing-and-submitting-inclusion-and-diversity-plan-second-draft\/. Accessed 12 May 2025."},{"key":"9566_CR20","unstructured":"Pharmaceutical Research and Manufacturers of America. Industry efforts to enhance clinical trial diversity. Washington (DC): PhRMA; 2022."},{"key":"9566_CR21","unstructured":"Pfizer. Pfizer awards $1.75 million to support Community Forward Solutions address health. https:\/\/www.pfizer.com\/news\/announcements\/pfizer-awards-175-million-support-community-forward-solutions-address-health. Accessed 26 May 2025."},{"key":"9566_CR22","unstructured":"Innovative Health Initiative. READI project factsheet. https:\/\/www.ihi.europa.eu\/projects-results\/project-factsheets\/readi. Accessed 12 May 2025."},{"key":"9566_CR23","unstructured":"Trial Forge. The INCLUDE ethnicity framework. https:\/\/www.trialforge.org\/trial-diversity\/include\/. Accessed 12 May 2025."},{"key":"9566_CR24","volume-title":"Achieving diversity, inclusion, and equity in clinical research toolkit","author":"BE Bierer","year":"2021","unstructured":"Bierer BE, White SA, Meloney LG, Ahmed H, Strauss DH, Clark LT. Achieving diversity, inclusion, and equity in clinical research toolkit. Cambridge (MA): Multi-Regional Clinical Trials Center of Brigham and Women\u2019s Hospital and Harvard; 2021."},{"key":"9566_CR25","volume-title":"Achieving diversity, inclusion, and equity in clinical research guidance","author":"BE Bierer","year":"2021","unstructured":"Bierer BE, White SA, Meloney LG, Hayat AR, Strauss DH, Clark LT. Achieving diversity, inclusion, and equity in clinical research guidance. Cambridge (MA): Multi-Regional Clinical Trials Center; 2021."},{"issue":"12","key":"9566_CR26","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1038\/s41591-023-02665-1","volume":"29","author":"A Retzer","year":"2023","unstructured":"Retzer A, Ciytak C, Khatsuria N, Juma EA, Isobel HM, Chapman L, et al. A toolkit for capturing a representative and equitable sample in health research. Nat Med. 2023;29(12):2991\u20139.","journal-title":"Nat Med"},{"key":"9566_CR27","volume-title":"Collaboration hub sponsor toolkit: portfolio and program-level considerations for diversity, equity and inclusion of participants in clinical trials (DEICT)","author":"TransCelerate BioPharma Inc.","year":"2022","unstructured":"TransCelerate BioPharma Inc. Collaboration hub sponsor toolkit: portfolio and program-level considerations for diversity, equity and inclusion of participants in clinical trials (DEICT). Philadelphia: TransCelerate BioPharma Inc.; 2022."},{"key":"9566_CR28","unstructured":"Clinical Trials Transformation Initiative. Recommendations for improving diversity in clinical trials. https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2023\/05\/CTTI_Diversity_Recommendations_FINAL.pdf. Accessed 16 May 2025."},{"key":"9566_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12874-020-01061-4","volume":"20","author":"N McMeekin","year":"2020","unstructured":"McMeekin N, Wu O, Germeni E, Briggs A. How methodological frameworks are being developed: evidence from a scoping review. BMC Med Res Methodol. 2020;20:173.","journal-title":"BMC Med Res Methodol"},{"key":"9566_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13643-021-01821-3","volume":"10","author":"MDJ Peters","year":"2021","unstructured":"Peters MDJ, Marnie C, Colquhoun H, Garritty CM, Hempel S, Horsley T, et al. Scoping reviews: reinforcing and advancing the methodology and application. Syst Rev. 2021;10:263.","journal-title":"Syst Rev"},{"key":"9566_CR31","doi-asserted-by":"publisher","first-page":"238212052513456","DOI":"10.1177\/23821205251333034","volume":"12","author":"KA Hill","year":"2025","unstructured":"Hill KA, Austin AW, Enders FT. A scoping review of interventions to promote diversity, equity, and inclusion in the United States healthcare workforce. J Med Educ Curric Dev. 2025;12:23821205251345678.","journal-title":"J Med Educ Curric Dev"},{"issue":"6","key":"9566_CR32","first-page":"2061","volume":"26","author":"LJ Goldsmith","year":"2021","unstructured":"Goldsmith LJ. Using framework analysis in applied qualitative research. Qual Rep. 2021;26(6):2061\u201376.","journal-title":"Qual Rep"},{"issue":"10","key":"9566_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/jor.25678","volume":"41","author":"D Little","year":"2023","unstructured":"Little D, Amadio PC, Awad HA, Cone SG, Dyment NA, Fisher MB, et al. Preclinical tendon and ligament models: beyond the 3Rs to 5W1H. J Orthop Res. 2023;41(10):2301\u201314.","journal-title":"J Orthop Res"},{"key":"9566_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","volume":"67","author":"J O\u2019Neill","year":"2014","unstructured":"O\u2019Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol. 2014;67:56\u201364.","journal-title":"J Clin Epidemiol"},{"key":"9566_CR35","doi-asserted-by":"crossref","first-page":"100437","DOI":"10.1016\/j.puhip.2023.100437","volume":"6","author":"L McCann","year":"2023","unstructured":"McCann L, Johnson L, Ford J. Equity-focused evidence synthesis: a need to optimise our approach. Public Health Pract. 2023;6:100437.","journal-title":"Public Health Pract"},{"key":"9566_CR36","doi-asserted-by":"publisher","first-page":"e089654","DOI":"10.1136\/bmjopen-2024-091807","volume":"15","author":"K Gedela","year":"2025","unstructured":"Gedela K, Wong R, Balendra S, Chita S, Jones H, Golombek R, et al. Embedding equity, diversity and inclusion processes within clinical trials and health and social care research. BMJ Open. 2025;15:e089654.","journal-title":"BMJ Open"},{"issue":"1","key":"9566_CR37","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s13063-020-04613-7","volume":"21","author":"M Witham","year":"2020","unstructured":"Witham M, Anderson E, Carroll C, Dark P, Down K, Hall AS, et al. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials. 2020;21(1):694.","journal-title":"Trials"},{"key":"9566_CR38","unstructured":"Canadian Cancer Clinical Trials Network. Equity, diversity and inclusion framework. https:\/\/3ctn.ca\/wp-content\/uploads\/2024\/08\/EDI-Framework.pdf. Accessed 12 May 2025."},{"issue":"6","key":"9566_CR39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cncr.21745","volume":"106","author":"S Bolen","year":"2006","unstructured":"Bolen S, Tilburt J, Baffi C, Gary TL, Powe N, Howerton M, et al. Defining success in recruitment of underrepresented populations to cancer clinical trials. Cancer. 2006;106(6):1197\u2013204.","journal-title":"Cancer"},{"issue":"3","key":"9566_CR40","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.patter.2024.100944","volume":"5","author":"B Theodorou","year":"2024","unstructured":"Theodorou B, Glass L, Xiao C, Sun J. FRAMM: fair ranking with missing modalities for clinical trials. Patterns (N Y). 2024;5(3):100944.","journal-title":"Patterns (N Y)"},{"key":"9566_CR41","volume-title":"Equity by design in clinical research: the Ebd metrics framework","author":"W DeCormier Plosky","year":"2022","unstructured":"DeCormier Plosky W, Meloney LG, Ahmed HR, White SA, Bierer BE. Equity by design in clinical research: the Ebd metrics framework. Cambridge (MA): Multi-Regional Clinical Trials Center of Brigham and Women\u2019s Hospital and Harvard; 2022."},{"key":"9566_CR42","volume-title":"Global diversity, equity and inclusion roadmap","author":"Multi-Regional Clinical Trials Center","year":"2024","unstructured":"Multi-Regional Clinical Trials Center. Global diversity, equity and inclusion roadmap. Boston: Multi-Regional Clinical Trials Center of Brigham and Women\u2019s Hospital and Harvard; 2024."},{"key":"9566_CR43","doi-asserted-by":"publisher","first-page":"107179","DOI":"10.1016\/j.cct.2023.107184","volume":"129","author":"MR Cullen","year":"2023","unstructured":"Cullen MR, Lemeshow AR, Amaro S, Bandera EV, Cooper LA, Kawachi I, et al. A framework for setting enrollment goals to ensure participant diversity in sponsored clinical trials in the United States. Contemp Clin Trials. 2023;129:107179.","journal-title":"Contemp Clin Trials"},{"key":"9566_CR44","unstructured":"ICON. Taking a proactive and holistic approach to diversity assessment and planning. https:\/\/webinars.iconplc.com\/detail\/video\/6338973565112\/taking-a-proactive-and-holistic-approach-to-diversity-assessment-and-planning. Accessed 25 Jul 2025."},{"key":"9566_CR45","volume-title":"Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: guidance for industry (draft)","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: guidance for industry (draft). Silver Spring (MD): U.S. Food and Drug Administration; 2024."},{"key":"9566_CR46","unstructured":"NHS Health Research Authority. Increasing the diversity of people taking part in research. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/best-practice\/increasing-diversity-people-taking-part-research\/. Accessed 1 Jun 2025."},{"key":"9566_CR47","unstructured":"Bierer BE, DeCormier Plosky W, Hanger M, Krofah E, Long Y, et al. Toward a national action plan for achieving diversity in clinical trials. Washington (DC): Milken Institute; 2024."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09566-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09566-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09566-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:36:57Z","timestamp":1774618617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09566-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9566"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09566-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7978721\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this work because it comprised expert consultation and co-design to refine a methodological tool and did not involve human-subjects research. Advisory board members were invited for their professional expertise; they were not the object of study and no sensitive data was collected or analyzed about the individuals, and therefore no identifiable sensitive individual-level information is reported. Experts participated under a paid consultancy arrangement and could decline or discontinue involvement. All advisory board members were informed of the purpose of the activity and the intention to publish the resulting methodology, and they consented to participate. Feedback was used only in de-identified, aggregated form to refine the methodology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}